Table 2 The prevalence of SLCO1B1 С521Т genotypes (Group A) and MDR1 С3435Т genotypes (Group B) in patients with HDH who underwent statin treatment (Rosuvastatin, Atorvastatin and Simvastatin)
Subgroup | Genotypes | ||
|---|---|---|---|
SLCO1B1 С521Т (Group A) | |||
521СС | 521ТТ | 521ТС | |
Subgroup AI (Rosuvastatin, n = 30) | 6 (20.0%) | 15 (50.0%) | 9 (30.0%) |
Subgroup AII (Atorvastatin, n = 30) | 6 (20.0%) | 16 (53.3%) | 8 (26.7%) |
Subgroup AIII (Simvastatin, n = 30) | 8 (26.7%) | 12 (40.0%) | 10 (33.3%) |
MDR1 С3435Т (Group B) | |||
3435СС | 3435ТТ | 3435СТ | |
Subgroup BI (Rosuvastatin, n = 30) | 8 (26.7%) | 7 (23.3%) | 15 (50.0%) |
Subgroup BII (Atorvastatin, n = 30) | 9 (30.0%) | 7 (23.3%) | 14 (46.7%) |
Subgroup BIII (Simvastatin, n = 30) | 7 (23.3%) | 8 (26.7%) | 15 (50.0%) |